Vigil Neuroscience is a company.
Vigil Neuroscience has raised $90.0M across 1 funding round.
Key people at Vigil Neuroscience.
Vigil Neuroscience has raised $90.0M in total across 1 funding round.
Vigil Neuroscience is a clinical-stage biotechnology company developing therapies for rare and common neurodegenerative diseases by restoring microglia function, the brain's sentinel immune cells.[1][2] Its lead product, VGL101 (iluzanebart), is a monoclonal antibody TREM2 agonist in Phase 2 trials for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare fatal disease, while VG-3927, an oral small molecule TREM2 agonist, targets Alzheimer's in Phase 1.[1][5] The company serves patients, caregivers, and families affected by these conditions, addressing microglial dysfunction—a key driver of neuroinflammation and neurodegeneration—through innovative small and large molecule drugs.[2][3] With 69 employees, no approved products yet, and a market cap around $137M as of recent data, Vigil shows early clinical momentum via ongoing trials but remains pre-revenue with losses.[1][3]
Vigil Neuroscience was incorporated on June 22, 2020, and is headquartered in Watertown, Massachusetts.[1][5] It emerged from microglia-focused research, backed by early ties to investors like Atlas Venture, with a mission to pioneer TREM2-targeted therapies for CNS diseases.[4] Pivotal early moments include securing a license agreement with Amgen for TREM2-binding compounds and launching its IPO on January 7, 2022, raising $98M at $14 per share on NASDAQ (VIGL).[1][6] Led by CEO Ivana Magovcevic-Liebisch, the team includes key experts like Chief Scientific Officer Dr. David Gray, emphasizing rapid advancement from startup to clinical-stage operations.[1]
Vigil rides the surging trend of neuroimmunology, where microglia dysfunction is increasingly linked to Alzheimer's and rare leukodystrophies amid aging populations and genetic insights.[1][2][5] Timing aligns with TREM2's validation as a therapeutic target via recent genetic studies, bolstered by market forces like rising neurodegenerative prevalence (e.g., 50M+ Alzheimer's cases globally) and biotech investment in precision CNS drugs.[4] It influences the ecosystem by advancing disease-modifying therapies in a field dominated by symptom management, potentially paving the way for microglia modulation platforms and collaborations with big pharma like Amgen.[1][3]
Vigil's path hinges on Phase 2 ALSP data for VGL101 and Phase 1 readout for VG-3927, with potential expansion to Alzheimer's subpopulations if TREM2 agonism proves safe and efficacious.[1][5] Trends like AI-driven patient stratification and combo immunotherapies could accelerate progress, though funding pressures in a tight biotech market pose risks given its $137M cap and losses.[3][6] Success here could redefine microglia as a cornerstone of neurodegeneration treatment, restoring Vigil's early promise from 2020 inception to transformative impact.[2]
Key people at Vigil Neuroscience.
Vigil Neuroscience has raised $90.0M in total across 1 funding round.
Vigil Neuroscience's investors include Vida Ventures.
Vigil Neuroscience has raised $90.0M across 1 funding round. Most recently, it raised $90.0M Series B in August 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2021 | $90.0M Series B | Vida Ventures |
